Im Jong-hoon, the CEO of Hanmi Pharmaceutical and the second son of the late founder of Hanmi Group, Lim Sung-ki, has agreed to sell a 2.5% stake in Hanmi Science.
According to a report by Yonhap News and the Financial Supervisory Service's electronic disclosure system on July 2, Im will dispose of 1,709,788 shares, representing 2.5% of his holdings in Hanmi Science.
The shares will be sold at a price of 48,000 won each, totaling approximately 82.07 billion won. The buyer is reported to be a private equity fund.
Once the transaction is completed, Im's stake in Hanmi Science will decrease from 5.09% to 2.59%.
Im stated through Hanmi that this decision was made to sincerely continue his father's management philosophy and vision. He added, "Together with my mother and sister, I will fulfill all roles that contribute to the company's development in order to carry on my father's dream of 'Pharmaceuticals for the Nation.'"
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.